First Multikilogram Synthesis of the Next-Generation Oral Selective ERα Degrader Camizestrant

已完结 10 由小太阳发布于 2024/6/12 8:56:39

DOI:10.1021/acs.oprd.4c00135
作者：Matthew R. Tatton, Gordon S. Currie, Bradley Adams, Carl-Johan Aurell, Karl Broberg, Andrew D. Campbell, Kuangchu Dai, Marcus Malmgren, Andrew Ikin, Sophie L. M. Janbon, Martin Sims, Joanna Hemming-Taylor, Victoria Winterbottom
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：Camizestrant is currently being investigated in multiple Phase 3 clinical trials for ER+ breast cancer. This article describes our efforts toward the first manufacture of clinical material.

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierExploring the characteristics of Burkholderia gladioli pathovar cocovenenans: Growth, bongkrekic acid production, and potential risks of food contamination in wet rice noodles and vermicelli